← Back to Search

Anti-metabolites

Arm A (decitabine or azacitidine) for Myelodysplastic Syndrome (ICT-HCT Trial)

Phase 2

Waitlist Available

Led By Bart L. Scott

Research Sponsored by Fred Hutchinson Cancer Research Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 18 months

Awards & highlights

ICT-HCT Trial Summary

This trial is testing different chemotherapies to see which is most effective in treating patients with myelodysplastic syndrome before a donor stem cell transplant.

Eligible Conditions

de Novo Myelodysplastic Syndrome
Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia

ICT-HCT Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 18 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~18 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Failure-free Survival (Failure Defined as Death or Relapse)

Secondary outcome measures

Number of Participants Who Received a Hematopoietic Cell Transplantation (HCT).

Number of Patients Who Relapse Post-transplant

Overall Survival

+2 more

ICT-HCT Trial Design

2Treatment groups

Experimental Treatment

Group I: Arm B (induction-like chemotherapy regimen)Experimental Treatment1 Intervention

Patients receive physician choice of standard of care or other experimental protocol using induction-like chemotherapy regimen. No one specific regimen is required. Several regimens are listed in the protocol for example only.

Group II: Arm A (decitabine or azacitidine)Experimental Treatment3 Interventions

Patients receive decitabine or azacitidine IV or SC per standard of care. Treatment repeats per standard of care, every 28 days for 4 cycles of decitabine or 6 cycles of azacitidine in the absence of disease progression or unacceptable toxicity.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Decitabine

2004

Completed Phase 3

~1680

Azacitidine (AZC)

2013

Completed Phase 2

~50

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Fred Hutchinson Cancer Research CenterLead Sponsor

443 Previous Clinical Trials

148,195 Total Patients Enrolled

Fred Hutchinson Cancer CenterLead Sponsor

556 Previous Clinical Trials

1,343,218 Total Patients Enrolled

Bart L. ScottPrincipal InvestigatorFred Hutch/University of Washington Cancer Consortium

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the potential risks associated with this treatment?

"While there is some data suggesting this treatment is safe, it's efficacy has yet to be supported. Therefore, it received a score of 2."

Answered by AI

Is this study still open to new participants?

"This particular study has concluded recruitment, with its last update on June 8th, 2022. At the present moment, there are 1685 other studies for de novo myelodysplastic syndromes and 272 trials concerning this treatment that are still recruiting patients."

Answered by AI

What are the indications for this type of therapy?

"This medication is often used to help patients during induction chemotherapy, but it can also be given to those suffering from ipss risk category intermediate-2, refractory anemias, and leukemia, myelocytic, acute."

Answered by AI

Could you please tell me what other research has been conducted on this therapy?

"Currently, there are a total of 272 ongoing trials for this intervention with 47 in the critical third phase. Most clinical trial sites investigating this treatment are located within Reggio Emilia and Foggia; however, 6600 different locations worldwide are running similar studies."

Answered by AI

How many people are being asked to participate in this experiment?

"Unfortunately, this clinical trial is not presently looking for candidates. The study was initially posted on 4/2/2013 and was last updated on 6/8/2022. However, there are 1685 trials actively recruiting participants with de novo myelodysplastic syndromes and 272 trials for this treatment actively enrolling participants if you are willing to look into other studies."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant

Bart Scott 2013. "Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01812252.